Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC)
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242015284 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Enrique Recuero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Carcinoma, Small Cell, Lung Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, FEDER and the European Union, Comunidad de Madrid.
Abstract (Originalsprache)
There is a clear need to expand the toolkit of adequate mouse models and cell lines available for preclinical studies of high-grade neuroendocrine lung carcinoma (small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC)). SCLC and LCNEC are two highly aggressive tumor types with dismal prognoses and few therapeutic options. Currently, there is an extreme paucity of material, particularly in the case of LCNEC. Given the lack of murine cell lines and transplant models of LCNEC, the need is imperative. In this study, we generated and examined new models of LCNEC and SCLC transplantable cell lines derived from our previously developed primary mouse LCNEC and SCLC tumors. RNA-seq analysis demonstrated that our cell lines and syngeneic tumors maintained the transcriptome program from the original transgenic primary tumor and displayed strong similarities to human SCLC or LCNEC. Importantly, the SCLC transplanted cell lines showed the ability to metastasize and mimic this characteristic of the human condition. In summary, we generated mouse cell line tools that allow further basic and translational research as well as preclinical testing of new treatment strategies for SCLC and LCNEC. These tools retain important features of their human counterparts and address the lack of LCNEC disease models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain.
- Institute of Biomedical Research Hospital "12 de Octubre" (imas12), 28041 Madrid, Spain.
- Tumor Progression Mechanisms Program, CIBERONC, Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.
- Pathology Department, University Hospital "12 de Octubre", 28041 Madrid, Spain.
ORCID-Profile: Sara Lázaro, Corina Lorz, Ramón Garcia-Escudero
Förderung
- Instituto de Salud Carlos III
- FEDER and the European Union
- Comunidad de Madrid
Zitieren
APA
Recuero, E., Lázaro, S., Lorz, C., Enguita, A. B., Garcia-Escudero, R., & Santos, M. (2023). Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015284
Vancouver
Recuero E, Lázaro S, Lorz C, Enguita AB, Garcia-Escudero R, Santos M. Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC). International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015284
BibTeX
@article{Recuero2023,
author = {Recuero, Enrique and Lázaro, Sara and Lorz, Corina and Enguita, Ana Belén and Garcia-Escudero, Ramón and Santos, Mirentxu},
title = {Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC)},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242015284}
}
EUVIMED